Advent firms up deal for Sanofi in Europe
Advent International and Sanofi have struck a final deal for the private-equity investment group to acquire Sanofi’s European generics business, Zentiva, through a share purchase agreement worth €1.9 billion (US$2.2 billion). The deal comes after the completion of exclusive negotiations that were announced by the two companies in mid-April (Generics bulletin, 20 April 2018, page 1).
You may also be interested in...
Zentiva has announced that it is investing a further €27m in expanding its flagship manufacturing plant in Prague, having already pumped €35m into the site over the past three years.
Zentiva is opening a dedicated Indian office in Mumbai to support the Ankleshwar manufacturing facility that it has just acquired from former parent company Sanofi.
Zentiva has struck a deal to acquire a manufacturing site in Ankleshwar, India, from its former parent company Sanofi.